hmpl-a830
hmpl-a830: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: HUTCHMED (China) Limited (HCM)
Development Pipeline (1)
| Company | Phase |
|---|---|
| HUTCHMED (China) Limited (HCM) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase I/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A830 in Solid Tumors
Frequently asked questions
Who is developing hmpl-a830?
hmpl-a830 is being developed by HUTCHMED (China) Limited.
How many clinical trials involve hmpl-a830?
BioSniper tracks 1 clinical trial involving hmpl-a830.
Analyze HUTCHMED (China) Limited & hmpl-a830 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company